ロード中...
Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
Acute myelogenous leukemia (AML) is frequently accompanied by a poor prognosis. The majority of patients with AML will experience recurrence due to multiple drug resistance. Our previous study reported that targeting the mTOR pathway may increase cell sensitivity to doxorubicin (Doxo) and provide an...
保存先:
| 出版年: | Mol Med Rep |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930928/ https://ncbi.nlm.nih.gov/pubmed/34223631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2021.11940 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|